Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 5/20 | 0.32 |
| ▸ | CCR3 | P51677 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11154317 | 1.00 | ACE (0.32) | ACECCR3MEN1KMT2AALDH1A1 | |
| SCHEMBL10437914 | 0.98 | CCR3 (0.31) | ACECCR3MEN1KMT2AALDH1A1 | |
| SCHEMBL29957169 | 0.93 | ACE (0.32) | ACEMEN1KMT2A | |
| SCHEMBL9527119 | 0.86 | ACE (0.40) | ACE | |
| SCHEMBL124448 | 0.86 | ACE (0.37) | ACE | |
| Hydrochloric Acid SCHEMBL9864881 | 0.85 | ACE (0.36) | ACEALDH1A1 | |
| SCHEMBL1979266 | 0.85 | CNR2 (0.37) | ACEALDH1A1 | |
| SCHEMBL2494405 | 0.84 | ACE (0.42) | ACE | |
| SCHEMBL15664979 | 0.84 | ACE (0.42) | ACE | |
| SCHEMBL206311 | 0.84 | ACE (0.42) | ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3498717-B1 | COMPOSITION FOR HARDENING SOFT TISSUE | CATHOLIC UNIV KOREA IND ACADEMIC COOPERATION FOUNDATION (KR) | 2022-05-04 | — | — | EP | claimed |
| US-20150072957-A1 | Tazobactam Arginine Compositions | CALIXA THERAPEUTICS, INC. (US) | 2015-03-12 | — | — | US | claimed |
| WO-2010078258-A1 | COMPOUNDS COMPRISING TWO OR MORE BIOLOGICALLY FUNCTIONAL IONS AND METHOD OF TREATING PARKINSON'S DISEASE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-07-08 | — | — | WO | claimed |
| WO-2024103010-A1 | SMALL MOLECULE INHIBITORS OF KRAS PROTEINS | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| EP-4028404-A2 | PENAM DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Tennor Therapeutics Limited (CN) | 2022-07-20 | — | — | EP | disclosed |
| CN-112724162-B | Synthesis method and application of amoxicillin-sulbactam hybrid molecule | 华南农业大学 | 2022-06-10 | — | — | CN | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| EP-3426662-A1 | SYNTHESIS PROCESS OF PRECURSORS OF DERIVATIVES OF -LACTAM NUCLEI AND PRECURSORS AND DERIVATIVES THEREOF | Bonomi, Paolo (FR) | 2019-01-16 | — | — | EP | disclosed |
| US-20180021259-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-01-25 | — | — | US | disclosed |
| WO-2017153892-A1 | SYNTHESIS PROCESS OF PRECURSORS OF DERIVATIVES OF β-LACTAM NUCLEI AND PRECURSORS AND DERIVATIVES THEREOF | BONOMI PAOLO (FR) | 2017-09-14 | — | — | WO | disclosed |
| EP-0907653-A1 | PROCESS FOR THE PREPARATION OF PENAM AND PENEM DERIVATIVES | ZENECA LIMITED (GB) | 1999-04-14 | — | — | EP | disclosed |
| EP-0906312-A1 | PROCESS FOR THE PREPARATION OF CARBAPENEM DERIVATIVES AND INTERMEDIATES THEREOF | ZENECA LIMITED (GB) | 1999-04-07 | — | — | EP | disclosed |
| WO-1998000429-A1 | PROCESS FOR THE PREPARATION OF PENAM AND PENEM DERIVATIVES | ZENECA LIMITED (GB) | 1998-01-08 | — | — | WO | disclosed |
| WO-1997047621-A1 | PROCESS FOR THE PREPARATION OF CARBAPENEM DERIVATIVES AND INTERMEDIATES THEREOF | ZENECA LIMITED (GB) | 1997-12-18 | — | — | WO | disclosed |
| WO-1993008287-A1 | NOVEL BIOPROCESSES FOR PREPARING 7-ACA AND 7-ADAC | MERCK & CO., INC. (US) | 1993-04-29 | — | — | WO | disclosed |
| EP-0367124-A1 | Penicillanic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-05-09 | — | — | EP | disclosed |
| EP-0091576-B1 | 7-OXO-4-THIA-1-AZABICYCLO(3,2,0)HEPTANE DERIVATIVES | HOECHST UK LIMITED (GB) | 1987-07-29 | — | — | EP | disclosed |
| EP-0000645-B1 | ISOPENICILLINS, PROCESSES FOR THEIR PREPARATION, AND COMPOSITIONS CONTAINING THEM | SMITHKLINE BECKMAN CORPORATION (US) | 1981-01-28 | — | — | EP | disclosed |
| EP-0002564-A1 | Derivatives of 7-oxo-1-azabicyclo(3.2.0)-hept-2-ene-2-carboxylic acid, their preparation, pharmaceutical compositions containing them and intermediates | BEECHAM GROUP PLC (GB) | 1979-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021259-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | TP53, HCCS, SCNN1B | ACE 4229/4885CCR3 2087/4885MEN1 3720/4885 |
| US-20150072957-A1 | Tazobactam Arginine Compositions | PRMT6, PRMT9, PRMT3 | ACE 3348/4885CCR3 3690/4885MEN1 3175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.